[Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]]

J Dtsch Dermatol Ges. 2009 Apr;7(4):291-2. doi: 10.1111/j.1610-0387.2009.07079.x.
[Article in German]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Dermatology / standards*
  • Germany
  • Humans
  • Leukoencephalopathy, Progressive Multifocal / drug therapy
  • Leukoencephalopathy, Progressive Multifocal / etiology
  • Practice Guidelines as Topic*
  • Psoriasis / drug therapy
  • Societies, Medical

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • efalizumab